Management Development

Ramin Rahbari MS,MBA

*** **** **** ****** *** York, NY 10065 M: 734-***-**** *****.*******@*****.***

Consulting Post Merger Integration Change Management Translational Research

SUMMARY

Over 19 years of experience in the life science industry that includes drug research and development, translational medicine, precompetitive collaboration, project leadership and management, portfolio management and prioritization, change management, post-merger integration and strategy consulting.

EDUCATION

Cornell University, Johnson Graduate School of Business, Ithaca, NY, USA 2011

Masters of Business Administration; Finance, Entrepreneurship, Negotiation, Operations

University of Michigan, Stephen M. Ross School of Business, Ann Arbor, MI, USA 2006

Executive Education Certificate Program; Management I, II, III, Empowerment, Managing the Unexpected

Eastern Michigan University, Ypsilanti, Michigan, USA 1996

Masters of Science; Cellular and Molecular Biology, Biochemistry

Eastern Michigan University, Ypsilanti, Michigan, USA 1993

Bachelor of Science; Biology and Economics

STRENGTHS

An experienced and proven strategic consultant to senior management

Adept in describing the competitive landscape and driving consensus across stakeholders

A published translational research SME with established networks across multiple disciplines

A track record of success in turn around projects in unprecedented and ambiguous settings

Experienced technology hunter with a record of having acquired and implement novel platforms

Demonstrated track record of successfully forming and leading high functioning work streams

Functioned as a matrixed leader, informed risk taker, innovation promoter and team leader

Extensive experience with process harmonization, staff development and engagement efforts

EXPERIENCE

Cognizant Technology Solutions, Teaneck, NJ, USA 10/2012-12/2015

Associate Director - Cognizant Business Consulting

Life Sciences R&D Lead, Translational Science SME

Research the competitive landscape and provide strategic and operational input

Engage multi-national clients with transformational projects across sites, lines and geographies

Design implementation roadmaps in accordance with client needs, goals and capabilities

Lead multiple work streams for post-merger integration and reorganization

Function as SME on projects in the Research & Development space within the life sciences arena

Refine decision making models to optimize discovery target selection, biomarker development, and portfolio management tools for both the internal and the extended portfolio of the client

Conduct pre-sale interviews, define strategic direction, and present proposal packages

Maintain relationships with clients, conduct BD meetings, support and contribute to sales targets

EXPERIENCE

IBM Global Business Services, New York, NY, USA 4/2012-10/2012

Managing Consultant – Strategy & Transformation

Leveraged IBM proprietary platforms (Watson) to create partnerships with marquee companies

Engaged stakeholders and designed strategic roadmaps to optimize & transform business processes

Served as SME to IBM projects (US, UK) engaged in the Research & Development and Clinical spaces

Innovative Scientific Management, New York, NY, USA 2007- 2012

Partner - Senior Consultant

Assessed multiple health care markets and partners for points of entry and arbitrage opportunities

Generated strategy, identified partners, established alliances, negotiated strategic direction and operational terms to facilitate executing on Biomarker and Rx/Rd licensing strategies

Represented clients during interactions with KOLs, commercial, academic and regulatory parties

Provided scientific and operational expertise to clients regarding intellectual property, competitive landscape and marketing assessments of novel health insurance products

Pfizer Global Research & Development, Ann Arbor, MI, USA 1996-2007

Associate Research Fellow, Lead-Technology Center 2004-2007

Senior Principal Scientist, Chair-Biomarker Translation Team 2003-2004

Senior Scientist, Lead-Investigational Imaging 2002-2003

Senior Associate Scientist,* Discovery Toxicology-Image Analysis Laboratory 1998-2000

Senior Assistant Scientist,* Experimental Toxicology-Image Analysis Laboratory 1996-1998

Point of accountability for biomarker implementation for the global portfolio

Generated the strategy, recruited the SMEs for the Biomarker Translation Team and implemented the solutions through the Technology Center resources and academic partners

Prioritized biomarker development requests for the Ann Arbor, Kalamazoo, St. Louis, Japan, Sandwich (UK), Amboise (France) sites in addition to joint venture Esperion Inc

Implemented a Service-Oriented Architecture to link multiple biomarker project databases post-merger and integration, gained immediate line of insight for the short horizon decisions and a list of desired capabilities and performance qualifications for an enterprise solution

Bridged the gap between focused and sharply demarcated entities of therapeutic areas, technical experts and business units. Capitalized on expertise and technology between poorly connected entities to facilitate cross pollination of best practices and expedited project completion

Formulated studies and responded to regulatory questions from US and EU regulatory bodies

Co-Designed a novel live cell imaging platform, negotiated a multi-party strategic alliance agreement and brought on line a unique platform for real time live-cell fluorescent imaging

Established and led strategic alliance agreements with Cedars-Sinai Medical Center,

University of Michigan, Carnegie Mellon University, Imperial College London, University of Surrey, Jet Propulsion Laboratory and NASA

Synaptic Pharmaceutical Corporation, Paramus, NJ, USA 2001-2001

Research Scientist II, Head-Screening & Cellular Sciences 8/2001-12/2001

Research Scientist I, Lead-Orphan GPCR Screening 3/2001-8/2001

Designed and validated a novel self-quenching reagent, 8x increased cycle times

Designed novel analysis algorithm and managed the implementation of proprietary data analysis package

SELECTED PUBLICATIONS

Bleavins, M.R. Darbyshire, J., and Rahbari, R. Biomarkers in Drug Discovery and Development: A Handbook of Discovery, Practice, Application, and Strategy, M. Bleavins, and R. Rahbari (Editor); John Wiley and Sons, Inc., Hoboken, NJ [In progress 2017].

Criswell K, Cook J, Morse D, Lawton M, Somps C, Roy M, Sokolowski S, Koza-Taylor P, Colangelo J, Navetta K, Brady J, Pegg D, Wojcinski Z, Rahbari R, Duddy S, Anderson T. Pregabalin Induces Hepatic Hypoxia and Increases Endothelial Cell Proliferation in Mice which is Attenuated by Dietary Vitamin E Supplementation. Toxicol Sci. 2012 Jul;128(1):42-56. doi: 10.1093/toxsci/kfs148. Epub 2012 Apr

S. Gad, J. Cavvangnaro, A. Nassar, P. Hollenberg, J. Scatina, M. Bleavins, C. Carini, M. Jurima-Romet,

R. Rahbari (Editor).. Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and Manufacturing. John Wiley & Sons, Inc, Hoboken, NJ; 2011. ISBN: 978**********; DOI:10.1002/978**********.

Bleavins, M. R., Carini, C., Jurima-Romet, M. and Rahbari, R. 2010. Biomarkers. Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and Manufacturing. John Wiley and Sons, Inc, Hoboken, NJ;

pp. 1–18, 2011. ISBN: 978**********; DOI:10.1002/978**********

Bleavins, M.R. and R. Rahbari. Biomarkers in Drug Development: A Handbook of Practice, Application, and Strategy, M. Bleavins, C. Carini, M. Jurima-Romet, and R. Rahbari (Editor); John Wiley and Sons, Inc., Hoboken, NJ pp. 551-564, 2010.

Bleavins, M.R. and R. Rahbari. The Anti-Unicorn Principle: Appropriate Biomarkers Don’t Need to be Rare or Hard to Find. In: Biomarkers in Drug Development: A Handbook of Practice, Application, and Strategy, edited by M.R. Bleavins, C. Carini, M. Jurima-Romet, and R. Rahbari, John Wiley and Sons, Inc., Hoboken, NJ pp. 551-564, 2010.

M.R. Bleavins, R. Rahbari, M. Jurima-Romet, and C. Carini. Biomarkers in Clinical Trials. In: Clinical Trials Handbook. Shayne Gad (Editor). John Wiley & Sons, Inc, Hoboken, NJ; pp. 851-868, 2009.

J. R. Haskins, P. Rowse, R. Rahbari and F.A. de la Iglesia. Thiazolidinedione toxicity to isolated hepatocytes revealed by coherent multiprobe fluorescence microscopy and correlated with multiparameter flow cytometry of peripheral lymphocytes. Arch. Toxicol. 75: 425-438, 2001.

J.R. Haskins, P.E. Rowse, R. Rahbari, F.A. de la Iglesia. Comparative Toxicity of Thiazolidinediones in Isolated rat Hepatocytes. Toxicological Sci 54: 43, 2000

D.R. Plymale, R. Rahbari, J.R. Haskins, F.A. de la Iglesia. In Vitro Subcellular Changes by Acridines in Human Hepatocytes. FASEB Journal 12:A798, 1998.

PROFESSIONAL SOCIETIES

American Association for Clinical Chemistry

Microscopy Society of America

American Association for the Advancement of Science

Society of Toxicology

The International Society for Optical Engineering; SPIE

The Society for Biomolecular Screening

Contact this candidate